Projects per year
Personal profile
Personal profile
Jenny Chang, MD, is the Director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and holds the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She is a Professor of Cancer with the Institute for Academic Medicine and a member of the Houston Methodist Research Institute and Professor at Weill Cornell Medical School. She obtained her medical degree at Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, and the role of targeting inflammatory pathways to change tumor immune microenvironment. Dr. Chang's clinical research aims to evaluate these novel biologic agents in breast cancer patients.
Research interests
Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.
Education/Academic qualification
MD, University of Cambridge
Aug 1 1986 → Dec 18 1990
Award Date: Dec 18 1990
Research Doctorate, University of London
External positions
Professor of Medicine, Weill Cornell Medical College, Cornell University
Research Area Keywords
- Cancer
- Systems Medicine & Bioinformatics
- Clinical Translation & Trials
Free-text keywords
- Cancer
- Stem cells
- Breast cancer
- High throughput
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Novel potential drug targets for treatment of triple-negative breast cancer
10/1/23 → 9/30/24
Project: Non Profit
-
Dual targeting of PI3K and NOS pathways in Metaplastic Breast Cancer (MBC)
7/8/23 → 6/30/28
Project: Federal Funding Agencies
-
Targeting Nitric Oxide Synthase (NOS) pathway to remodel obesity induced tumor inflammation in patients with TNBC
12/1/22 → 11/30/24
Project: State
-
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)
6/10/22 → 5/31/27
Project: Federal Funding Agencies
-
A Deep Learning Decision Support Tool to Improve Risk Stratification and Reduce Unnecessary Biopsies in BI-RADS 4 Mammograms
Ezeana, C. F., He, T., Patel, T. A., Kaklamani, V., Elmi, M., Brigmon, E., Otto, P. M., Kist, K. A., Speck, H., Wang, L., Ensor, J., Shih, Y. C. T., Kim, B., Pan, I. W., Cohen, A. L., Kelley, K., Spak, D., Yang, W. T., Chang, J. C. & Wong, S. T. C., Nov 2023, In: Radiology: Artificial Intelligence. 5, 6, p. e220259 e220259.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
A multicenter study validated an integrated deep learning model for precision malignancy risk assessment and reducing unnecessary biopsies in BI-RADS 4 cases
Wong, S. T., Ezeana, C. F., He, T., Patel, T., Kaklamani, V. G., Elmi, M., Ibarra, E., Otto, P. M., Kist, K. A., Speck, H., Wang, L., Ensor, Jr., J. E., Shih, Y-C. T., Bumyang, K., Pan, I-W., Spak, D., Yang, W. T. & Chang, J. C., Apr 4 2023, Proceedings of the American Association for Cancer Research Annual Meeting 2023: Cancer Res 2023;83(7_Suppl):Abstract nr 5698.Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
Open Access -
A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer
Guan, J., Sun, K., Guerrero, C. A., Zheng, J., Xu, Y., Mathur, S., Teh, B. S., Farach, A., Zhang, J., Butler, E., Pan, P. Y., Zsigmond, E., Mei, Z., Mejia, J., Chen, S. H., Chang, J. C. & Bernicker, E. H., Aug 24 2023, (E-pub ahead of print) In: International Journal of Radiation Oncology Biology Physics. 118, 5, p. 1531-1540 10 p.Research output: Contribution to journal › Article › peer-review
-
A Phase 2 study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*
Guan, J., Sun, K., Mathur, S., Chang, J. C. & Bernicker, E. H., 2023, (Unpublished) In: International Journal of Radiation Oncology Biology Physics.Research output: Contribution to journal › Article › peer-review
-
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer
Sun, K., Xu, Y., Mathur, S., Bernicker, E. H. & Chang, J. C., 2023, (Unpublished) In: Clinical Cancer Research. 25 p.Research output: Contribution to journal › Article › peer-review